Skip to main content
OpenTrials
Completed

NCT Number: NCT01010503

A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.

This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to non-biologic DMARDs. Patients will receive tocilizumab 8 mg/kg as intravenous infusion once every 4 weeks in combination with methotrexate or in case of intolerance to methotrexate as monotherapy. The anticipated time of study treatment is 6 months. The target sample size is 20-50 patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Piešťany, 921 12, Slovakia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patients >/= 18 years of age
  • moderate to severe active rheumatoid arthritis
  • inadequate response, or intolerance to previous therapy with one or more traditional DMARDs
  • DAS >3.6
  • pneumology examination (including chest x-ray and quantiferon)

Exclusion criteria

  • < 18 years of age
  • active infection
  • active tuberculosis
  • uncontrolled hyperlipoproteinaemia
  • demyelinating disorders
  • concomitant anti-TNF drugs
  • history of intestinal ulceration and diverticulitis

Treatment and study plan

tocilizumab [RoActemra/Actemra]

Drug

tocilizumab 8 mg/kg intravenous infusion once in 4 weeks

Primary outcomes

  1. Percentage of Participants Adherent to Original Treatment

    Time frame: Week 24

    Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely.

  2. Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

  3. Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

  4. Percentage of Participants Withdrawing From the Study Prematurely for Any Reason

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

  5. Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg

    Time frame: Weeks 0, 4, 8, 12, 16, and 20

Secondary outcomes

  1. Disease Activity Score Based on 28-Joint Count (DAS28)

    Time frame: Weeks 0, 4, 12, and 24

    DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.

  2. Patient Global Assessment of Pain

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

    Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured.

  3. Patient Global Assessment of Disease Activity

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

    The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured.

  4. Physician's Global Assessment of Disease Activity

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

    Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured.

  5. Swollen Joint Count (SJC)

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

    The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28.

  6. Tender Joint Count (TJC)

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

    The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28.

  7. Erythrocyte Sedimentation Rate (ESR)

    Time frame: Weeks 0, 4, 12, 20, and 24

    ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.

  8. C-Reactive Protein (CRP)

    Time frame: Weeks 0, 4, 12, 20, and 24

    CRP is an acute phase protein. Levels of CRP increase with inflammation.

  9. Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    Time frame: Weeks 0, 4, 8, 12, 16, 20, and 24

    The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.

  10. Short Form-36 (SF-36)

    Time frame: Weeks 0, 12, and 24

    The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Nov 10, 2009
Registry last updated
Aug 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.